New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
10:01 EDTTEVATeva receives positive CHMP opinion on clopidogrel / acetylsalicylic acid
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of a marketing authorization for the medicinal product Clopidogrel/Acetylsalicylic acid Teva. The applicant for this medicinal product is Teva Pharma. Reference Link
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent TEVA news | >>
June 18, 2015
15:41 EDTTEVATeva tender offer for Mylan likely imminent, says Citi
Citi said Teva (TEVA) is likely to build up a 4.6% stake in Mylan (MYL) by today and that a formal tender offer is likely coming soon. An official bid could come with a provision requiring board changes and a tender will likely trigger a "poison pill" by Mylan, the firm added. Citi has a Buy rating and $70 price target on Teva shares.
12:51 EDTTEVATeva guidance assumed launch of Copaxone generic, says BMO Capital
Subscribe for More Information
11:57 EDTTEVAMylan comments on ruling by appeals court on Copaxone patent
Subscribe for More Information
11:54 EDTTEVAAppeals court invalidates Teva patent claim related to Copaxone
Subscribe for More Information
10:41 EDTTEVAMomenta reports CAFC decision to invalidated remanded Teva patent
Subscribe for More Information
09:11 EDTTEVAAlexza Pharmaceuticals amends Adasuve commercial partnership agreements
Subscribe for More Information
08:34 EDTTEVATeva to present new data from Phase 2b migraine prevention studies at AHS
Subscribe for More Information
08:02 EDTTEVATeva, Microchips Biotech announce partnership agreement
Subscribe for More Information
07:36 EDTTEVAReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
06:09 EDTTEVATeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
June 17, 2015
07:12 EDTTEVANeurocrine price target raised to $87 from $63 at Piper Jaffray
Subscribe for More Information
June 16, 2015
14:23 EDTTEVAReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptos’ pipeline, and maintains an Outperform rating on the stock.
14:12 EDTTEVAAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
11:06 EDTTEVATeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
10:29 EDTTEVAGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
08:05 EDTTEVATeva reports ARM-TD study meets primary endpoint
Teva Pharmaceutical (TEVA) announced positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia, or ARM-TD, designed to evaluate the efficacy of SD-809 in the treatment of moderate to severe tardive dyskinesia. Top-line data showed that the study met its primary endpoint and demonstrated a positive trend in all secondary endpoints. The primary endpoint of ARM-TD was the change in the Abnormal Involuntary Movement Scale, or AIMS, from baseline to end of therapy, assessed by blinded centralized video rating. The study results show patients taking SD-809 achieved an improvement of 3.0 points on the AIMS score from baseline to end of therapy compared to 1.6 points in placebo for a clinically meaningful effect. Study results also demonstrated a favorable safety and tolerability profile of SD-809. Fewer patients taking SD-809 than placebo experienced serious adverse events. Three patients discontinued from the study for adverse events. For all other side effects reported in the study, rates in the SD-809 group were similar or lower than the placebo group. Further analysis of the additional data from the study is ongoing and details will be shared at future medical meetings and through peer-reviewed publication, the company said. SD-809 became part of Teva’s central nervous system product portfolio with the acquisition of Auspex Pharmaceuticals in May.
07:31 EDTTEVAEagle Pharmaceuticals price target raised to $95 from $65 at Cantor
Subscribe for More Information
June 15, 2015
09:16 EDTTEVAInternational Parkinson & Movement Disorder Society to hold a conference
9th International Congress of Parkinson's Disease and Movement Disorders is being held in San Diego, CA on June 14-18.
08:02 EDTTEVATeva announces FDA acceptance of BLA for Reslizumab
Teva Pharmaceutical Industries announced that the FDA has accepted for review the Biologics License Application for reslizumab, the company’s investigational humanized monoclonal antibody which targets interleukin-5, for the treatment of inadequately controlled asthma in adult and adolescent patients with elevated blood eosinophils, despite an inhaled corticosteroid based regimen. The BLA for reslizumab includes data from Teva’s Phase III BREATH clinical trial program. The program consisted of four separate placebo-controlled Phase III trials involving more than 1,700 adult and adolescent asthma patients with elevated blood eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroid-based therapies. Results from these studies demonstrated that reslizumab, in comparison to placebo, reduced asthma exacerbation rates by at least half and provided significant improvement in lung function and other secondary measures of asthma control when added to an existing ICS-based therapy. Common adverse events in the reslizumab treatment group were comparable to placebo and included worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache. Two anaphylactic reactions were reported and resolved following medical treatment at the study site.
06:02 EDTTEVATeva raises stake in Mylan to almost 3.5%, Globes reports
Subscribe for More Information
1 | 2 | all recent TEVA news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use